3 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMEDiabetic Macular Edema (DME)Active, not recruitingPhase 2 / Phase 32026-08-20NCT06957080
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in JapanHemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmActive, not recruitingNot stated2026-01-02NCT05228158
Phase III Trial of Stage I Ovarian Cancer After SurgeryAdnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorderRecruitingPhase 32019-08-30NCT04063527